

[Web](#) [Images](#) [Videos](#) [Maps](#) [News](#) [Shopping](#) [Gmail](#) [more ▾](#)[Web History](#) | [Search settings](#) | [Sign in](#)[Advanced Search](#)[Web](#) [Show options...](#)Results **11** - **20** of

Pinacidil-**diuretic** preparation for treating hypertension or ...

by E Arrigoni-martelli - 1983 - [Cited by 2](#) - [Related articles](#)A preparation as claimed in claim 1, in which the **diuretic** is a thiazide or ... of P 1134 can be further supported by using **sustained release** formulations. ...www.freepatentsonline.com/4409222.html - [Similar](#)

Data Sheet

The renal effects of Natrilix SR (**sustained release** film-coated tablet ... When Natrilix SR is given with other non **diuretic** antihypertensive agents, ...www.medsafe.govt.nz/profs/datasheet/n/NatrilixSRtab.htm - [Similar](#)

[PDF] **Sustained-Release** Diltiazem and Prevention of Cardiovascular Risk ...

File Format: PDF/Adobe Acrobat - [Quick View](#)-25 mm Hg for the **diuretic** (75% of the patients were responders in the diltiazem group vs. 50s in the **diuretic** group). **Sustained-release** diltiazem 300 mg ...yypharm.co.kr/data/docu/FT000230달티아젠텐서방_3.pdf

Burinex K **Sustained-release** tab drug information | MIMS Singapore

Burinex K **Sustained-release** tab - Bumetanide 0.5 mg, KCl 573 mg. ... of high-ceiling sulfonamide **diuretics** in combination with potassium. Used as **diuretic**. ...www.mims.com/Page.aspx?menuid=mng...Sustained-release... - [Cached](#)

Osmotic device containing diltiazem and an ACE inhibitor or ...

A wide range of ACE inhibitors or **diuretics** can be used in this device. ... 424/468,**Sustained** or differential **release** type424/474, Coated pills or ...www.patentstorm.us/patents/6569456.html

Beta blocker - Wikipedia, the free encyclopedia

Bisoprolol, carvedilol and **sustained-release** metoprolol are specifically indicated as adjuncts to standard ACE inhibitor and **diuretic** therapy in congestive ...en.wikipedia.org/wiki/Beta_blocker - 6 hours ago - [Cached](#) - [Similar](#)

Diuretics and β -Blockers: Is There a Risk for Dyslipidemia ...

In the Verapamil in Hypertension and Atherosclerosis Study, in which **sustained release** verapamil was compared with a thiazide **diuretic**, cholesterol levels ...www.medscape.com/viewarticle/409084__6

CA Patent 2092565 - IBUPROFEN-DIURETIC COMBINATIONS

Diuretic Sustained Release (S)-ibuprofen 400 mg. Hydrochlorothiazide 30 mg. PVP 30 mg. Avicel PH101 80 mg. Magnesium stearate 8 mg. Methocel E10MCR 66 mg ...www.wikipatents.com/CA-Patent.../ibuprofen-diuretic-combinations - [Cached](#)

Indomethacin **Sustained-Release** Capsules **Sustained-Release** Capsules ...

View complete and up to date Indomethacin **Sustained-Release** Capsules ... Potassium-sparing **diuretics** (eg, spironolactone, triamterene) because the risk of ...www.drugs.com/.../indomethacin-sustained-release-capsules.html - [Cached](#) - [Similar](#)

IngentaConnect Treating hypertension by rational use of **diuretics** ...

by ZD Kobalava - 2009 - [Related articles](#)

The objective of the ARGUS-2 study was to demonstrate that a rational use of a thiazide-like **diuretic**, indapamide **sustained release** (SR), ...
www.ingentaconnect.com/content/apl/cmro/2009/00000025/.../art00014

Previous [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) **Next**

sustained release diuretic

[Search within results](#) - [Language Tools](#) - [Search Help](#) - [Dissatisfied? Help us im](#)

[Google Home](#) - [Advertising Programs](#) - [Business Solutions](#) - [Priva](#)

Web Images Videos Maps News Shopping Gmail more ▾

Sign in

Google scholar

torsemide controlled release

Search

[Advanced Scholar Search](#)
[Scholar Preferences](#)

Scholar

Articles and patents ▾

anytime ▾

include citations ▾

Results **21 - 30** of about **1,16**

Diuretics

IV HF - Cardiac Drug Therapy - Springer

... Drug name: **Torsemide; torasemide** (UK) Trade names: Demadex, Torem (UK) Supplied: Tablets: 5, 10, 20, 100 mg Ampules: 50 mg Dosage: Oral: 2.5– 40 mg once daily; HF dose ...

Controlled-release preparations, K-Dur 20 (US) and K-Contin (UK), are safer than wax matrix ...

7 Diuretics

IV HF - Springer

... Drug name: **Torsemide; torasemide** (UK) Trade names: Demadex, Torem (UK) Supplied: Tablets: 5, 10, 20, 100 mg Ampules: 50 mg Dosage: Oral: 2.5– 40 mg once daily ... Mechanism of Action

Increased renin **release** from the juxtaglomerular cells is caused by several conditions: ...

[Related articles](#)

The efficiency concept in pharmacodynamics

G Alvan, G Paintaud, M ... - Clinical pharmacokinetics, 1999 - ingentaconnect.com

... [7] It was observed in 1982 that, although the bioavail- ability of a **controlled release** formulation of furo- semide was much lower than that of the plain tab- lets, their total diuretic and natriuretic effects were similar. ... **Controlled release Controlled release** Plain tablet IV dosage Fig. ...

[Cited by 14](#) - [Related articles](#) - [BL Direct](#) - [All 5 versions](#)

[HTML] Chronic heart failure: Essentials of optimal treatment

CME Calendar, P Recruitment, P Compensation, SMA ... - mediwire.sma.org

President's Welcome. Mission/Vision. Leadership. Special Service Awards. Press Releases. FAQ. Southern Medical Journal. CME Calendar. CME Online Library. Request a Brochure. Rate Your Practice. Practice Performance. Physician Relations. Financial Management. ...

[Related articles](#) - [Cached](#)

Gastric retentive oral dosage form with restricted drug **release** in the lower ...

B Berner, J Louie-Helm - US Patent App. 10/769,574, 2004 - Google Patents

... Cl.7 A61K 9/14 (52) US Cl 424/486 (57) **ABSTRACT Controlled release** oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. ...

[All 7 versions](#)

Dual drug dosage forms with improved separation of drugs

J Lim, JN Shell, J Louie-Helm... - US Patent App. 10/623,481, 2003 - Google Patents

... 30, 2001); and International (PCT) Patent Appli- cation WO 96/26718 ("**Controlled Release** Tablet," Kim ... converting enzyme inhibitor or angiotensin II antagonist occupies the pro- longed-**release** portion. ... Examples are furosemide, **torsemide**, ethacrynic acid, and bumetanide. ...

[All 6 versions](#)

Pharmacological treatment of chronic heart failure

R Adorisio, L De Luca, J Rossi, M Gheorghiade - Heart failure reviews, 2006 - Springer

... Until the **release** of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy ... In several clinical settings and placebo-**controlled** clinical trials of patients with chronic ... Currently available loop diuretics include furosemide, bumetanide, **torsemide**, and ethacrynic acid. ...

[Cited by 14](#) - [Related articles](#) - [BL Direct](#) - [All 3 versions](#)

Co-formulations or kits of bioactive agents

S Borsadia. . - US Patent App. 10/595,884, 2005 - Google Patents

... novel method of concurrently treating diabetes and co-morbidities, such as hypertension or dyslipidemia, by utilizing a multi-bioactive agent administration product to deliver a glucose level controlling bioactive agent, such as one which requires a **controlled release** dosage form ...

[All 2 versions](#)

Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral ...

MG Massironi - US Patent App. 10/493,901, 2002 - Google Patents

... 15. Compositions as claimed in claim 13 providing the **controlled-release** of the active ingredients. ... Minoxidil, Ketanserine, Hydrochlorothiazide, Chlortalidon, Metolazone, Xipamide, Indapamide, Fenquizone, Furosemide, Bumetamide, Pireta- mide, **Torsemide**, Etacrinic Acid ...

[All 6 versions](#)

Microparticles With Modified **Release** of At Least One Active Principle and Oral ...

F Dargelas, F Guilmerleau, C Castan, R Meyrueix, G ... - 2009 - freepatentsonline.com

... ranipril, reteplase, simvastatin, sotalol, spironolactone, streptokinase, telmisartan, terazosin, timolol, tocainamide, **torsemide**, trandolapril, triamteren ... of the determining advantages of the multimicroparticulate pharmaceutical formulation, with delayed and **controlled release** of AP ...



Result Page: [Previous](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [Next](#)

[Go to Google Home](#) - [About Google](#) - [About Google Scholar](#)

©2010 Google